WO2022257995A1 - 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 - Google Patents
一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 Download PDFInfo
- Publication number
- WO2022257995A1 WO2022257995A1 PCT/CN2022/097739 CN2022097739W WO2022257995A1 WO 2022257995 A1 WO2022257995 A1 WO 2022257995A1 CN 2022097739 W CN2022097739 W CN 2022097739W WO 2022257995 A1 WO2022257995 A1 WO 2022257995A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cryptotanshinone
- preparation
- derivative
- formula
- lowering
- Prior art date
Links
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical class O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 208000008589 Obesity Diseases 0.000 title abstract description 12
- 235000020824 obesity Nutrition 0.000 title abstract description 11
- 150000002632 lipids Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 22
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 230000003579 anti-obesity Effects 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 230000005526 G1 to G0 transition Effects 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 4
- 230000011759 adipose tissue development Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 238000010186 staining Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- -1 phentermine/topiramate compound Chemical class 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical class C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940042040 innovative drug Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940000306 phentermine / topiramate Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the invention relates to a novel cryptotanshinone derivative and its preparation method and application.
- the traditional Chinese medicine Salvia miltiorrhiza has significant effects of promoting blood circulation, removing blood stasis, and opening the heart envelope. It is used clinically in various forms, such as injections, dripping pills, tablets, etc. Its main medicinal ingredients are water-soluble salvianolic acid and fat-soluble tanshinone compounds.
- tanshinone IIA has been developed as a drug for treating angina pectoris, coronary heart disease and myocardial infarction.
- Myocardial fibrosis is generally a common pathological consequence of coronary atherosclerosis, characterized by excessive synthesis and pathological accumulation of extracellular matrix proteins in myocardial tissue, leading to myocardial stiffness and leading to diastolic heart failure.
- Obesity refers to a physical condition caused by a certain degree of fat accumulation in the body.
- the standard of obesity is often measured by body mass index (BMI), that is, weight divided by the square of height (kg/m 2 ).
- BMI body mass index
- BMI body mass index
- obesity is related to the occurrence of many diseases, which can be roughly divided into two categories: one is the effect caused by the increase in body fat mass (including sleep apnea and degenerative arthritis); the other is the effect caused by the increase in body fat cells effects (including cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, and cancer, etc.).
- body fat mass including sleep apnea and degenerative arthritis
- body fat cells effects including cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, and cancer, etc.
- cardiovascular disease including cardiovascular disease, type 2 diabetes, non-alcoholic fatty liver disease, and cancer, etc.
- the American Medical Association officially recognized obesity as a disease.
- the pathological process of the occurrence and development of obesity is very complex, caused by the interaction of multiple factors, including environmental factors (exercise and diet), genetic factors, endocrine imbalance or stress, epigenetic factors, insulin resistance, etc. It is difficult to develop new drugs.
- weight-loss drugs orlistat There are only five weight-loss drugs orlistat, locaserin hydrochloride, phentermine/topiramate compound preparations, and hypoglycemic drugs bupropion, naltrexone sustained-release tablets and liraglutide currently on the market.
- these weight-loss drugs have obvious side effects, and their safety and tolerability need to be confirmed. Therefore, it is of great research significance and application value to develop a new anti-obesity drug that can effectively inhibit the differentiation of adipocytes, reduce the lipid level in adipocytes and have low toxicity.
- most of the research is focused on molecular design and chemical synthesis, and few researchers have developed weight-loss drugs through the huge treasure house of natural products.
- the object of the present invention is to provide a novel cryptotanshinone derivative, a preparation method thereof and an application for reducing fat and resisting obesity.
- a first aspect of the present invention provides:
- a cryptotanshinone derivative and acceptable pharmaceutical salts thereof, the structural formula of the cryptotanshinone derivative is shown in Formula I:
- a second aspect of the present invention provides:
- the preparation method of the cryptotanshinone derivative described in the first aspect of the present invention comprises the following steps:
- the organic solvent is dioxymethane.
- oxalyl chloride is added in excess relative to cryptotanshinone.
- the reaction temperature is 20-30°C.
- the separation and purification method is forward silica gel column chromatography, using 300-400 mesh silica gel as the stationary phase; 5% dichloromethane-petroleum ether mixed solvent as the mobile phase, and can be separated and purified to obtain formula I compound.
- a third aspect of the present invention provides:
- a lipid-lowering or anti-obesity composition the active ingredient in the composition includes at least one of the cryptotanshinone derivatives and their acceptable pharmaceutical salts described in the first aspect of the present invention.
- the composition is an oral formulation.
- a fourth aspect of the present invention provides:
- a fifth aspect of the present invention provides:
- a method for lowering fat or losing weight comprising administering an effective amount of .
- greater than normal body weight refers to a body mass index (BMI) > 24.
- Fig. 1 is the proton nuclear magnetic resonance spectrum of the compound of formula I.
- Fig. 2 is the carbon spectrum and DEPT135 spectrogram of the compound of formula I.
- Fig. 3 is the result of the effect on the reduction rate of the TG content of triglyceride after being treated with different concentrations of the compound of formula I.
- Fig. 4 is the result of Oil Red O staining after treatment with 1 ⁇ M compound of formula I.
- Fig. 5 is the result of Oil Red O staining after treatment with 5 ⁇ M compound of formula I.
- Fig. 6 is the result of Oil Red O staining after treatment with 10 ⁇ M compound of formula I.
- the lipid-lowering test of the compound uses the mouse preadipocyte 3T3-L1 cell differentiation model, and uses Oil Red O staining combined with the quantitative detection of triglyceride to evaluate the effect of the anti-obesity compound provided by the present invention on the triglyceride content in adipocytes.
- 3T3-L1 preadipocytes in the logarithmic growth phase 5.0*10 4 cells/well, were evenly seeded into a 48-well plate, cultured in a cell incubator, and the culture medium was changed every two days.
- Differentiation induction medium I DMEM complete culture solution containing 500 ⁇ M 3-isobutyl-1-methyl-xanthine, 100 ng/mL dexamethasone, and 2 ⁇ g/mL insulin.
- Differentiation induction medium II DMEM complete culture medium containing 2 ⁇ M insulin with induction medium.
- the cells were rinsed once with pre-cooled PBS, and fixed with 4% frozen paraformaldehyde fixative at room temperature for 60 min. Stain with 0.3% Oil Red O staining working solution at room temperature for 30 min. Rinse with deionized water at room temperature for 2-3 times, and take pictures with an inverted microscope (40 times). Add 300uL of isopropanol solution to each well, shake the shaker gently at room temperature to extract Oil Red O dye for 30min, and pipette 100 ⁇ M dye solution for 510nm absorbance detection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用。隐丹参酮衍生物的结构式为。发明人首次制备得到了新的隐丹参酮衍生物。研究表明，该隐丹参酮衍生物可以有效的抑制脂肪生成，具有良好的安全性、较好的降脂活性，有望开发为新型的降脂抗肥胖症药物。
Description
本发明涉及一种新型的隐丹参酮衍生物及其制备方法和应用。
中药丹参具有显著的活血化瘀，通心包络的功效，以多种形式应用于临床，如注射液、滴丸、片剂等。其主要药效成分为水溶性的丹酚酸和脂溶性的丹参酮类化合物。在丹参酮类化合物中，丹参酮ⅡA已被开发为治疗心绞痛、冠心病和心肌梗死的药物。心肌纤维化一般是由冠状动脉粥样硬化引起的常见病理后果，特征是心肌组织中细胞外基质蛋白的过度合成和病理积累，导致心肌僵硬并导致舒张性心力衰竭。
肥胖是指一定程度的体内脂肪堆积而导致的一种身体状态。肥胖的标准常用身体质量指数(BMI)来衡量，即以体重除以身高的平方(kg/m
2)，当BMI大于30kg/m
2时即为肥胖。近年来，肥胖在全球流行。世界卫生组织称， 2016年有超过19亿成人超重， 6.5亿多人肥胖，每年至少有280万人死亡可归咎于超重或肥胖，并呈现出低龄化趋势。肥胖已然成为21世纪最重要的公共卫生问题之一。
研究表明，肥胖症与许多疾病的发生有关，大致可分为两类：一是因体脂肪量增加造成的影响(包括睡眠呼吸中止症、退化性关节炎)；二是体内脂肪细胞增加造成的影响(包括心血管疾病、二型糖尿病、非酒精性脂肪肝以及癌症等)。2013年，美国医学会正式把肥胖症认定为一种疾病。可是，由于肥胖症的发生和发展病理过程十分复杂，由多因素共同相互作用所致，包括环境因素(运动和饮食)、遗传因素、内分泌失衡或压力、表观遗传因素、胰岛素抵抗等，这给新药研发增加了难度。当前市场上仅有五种减肥药奥利司他、盐酸劳卡色林、芬特明/托吡酯复方制剂及降糖药物安非他酮纳曲酮缓释片和利拉鲁肽。但这些减肥药副作用明显，安全性和耐受性有待确认。因此，开发一种能够有效抑制脂肪细胞分化，降低脂肪细胞内脂质水平且毒性低的抗肥胖症新药具有重要的研究意义和应用价值。目前，研究大都集中在分子设计，化学合成上，极少有研究者通过天然产物这个巨大宝库去开发减肥药。
未有研究表明已有的隐丹参酮衍生物具有降脂抗肥胖的应用。
本发明的目的在于提供一种新型的隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用。
本发明所采取的技术方案是：
本发明的第一个方面，提供：
一种隐丹参酮衍生物及其可接受的药用盐，所述隐丹参酮衍生物的结构式如式Ⅰ所示：
本发明的第二个方面，提供：
本发明第一个方面所述隐丹参酮衍生物的的制备方法，包括如下步骤：
S1） 将隐丹参酮溶于有机溶剂中，加入草酰氯，搅拌反应充分，反应环境的相对湿度不低于80%；
S2） 将反应物分离纯化，得到式Ⅰ所示化合物。
在一些实例中，所述有机溶剂为二氧甲烷。
在一些实例中，草酰氯相对隐丹参酮过量加入。
在一些实例中，反应温度为20～30℃。
在一些实例中，所述分离纯化方法为正向硅胶柱色谱分离，以300～400目硅胶为固定相；5%的二氯甲烷-石油醚混合溶剂为流动相，即可分离纯化获得式Ⅰ化合物。
本发明的第三个方面，提供：
一种降脂或抗肥胖的组合物，所述组合物中的活性成分包括本发明第一个方面所述隐丹参酮衍生物及其可接受的药用盐中的至少一种。
在一些实例中，所述组合物为口服制剂。
本发明的第四个方面，提供：
本发明第一个方面所述隐丹参酮衍生物及其可接受的药用盐在制备降脂或抗肥胖组合物的中的应用。
本发明的第五个方面，提供：
一种降脂或减肥的方法，包括给予脂质水平大于或体重大于正常水平的人群给予有效量的
。
在一些方法的实例中，体重大于正常水平指身体质量指数(BMI)≥24。
发明人首次制备得到了新的隐丹参酮衍生物
(R)-1-chloro-2-(1-methoxypropan-2-yl)-8,8-dimethyl-5,6,7,8-tetrahydrophenanthrene-3,4-dione，研究表明，该隐丹参酮衍生物可以有效的抑制脂肪生成，具有较好的降脂活性，有望开发为新型的降脂抗肥胖症药物。
图1是式Ⅰ化合物的核磁共振氢谱。
图2是式Ⅰ化合物的碳谱和DEPT135谱图。
图3是不同浓度式Ⅰ化合物处理后的对甘油三酯TG含量降低率的影响结果。
图4是1μM式Ⅰ化合物处理后油红O染色结果。
图5是5μM式Ⅰ化合物处理后油红O染色结果。
图6是10μM式Ⅰ化合物处理后油红O染色结果。
本发明得到了项目名称为“炎症相关性重大疾病创新药物研发及关键技术”(编号2017BT01Y093)的资助。
下面结合实验，进一步说明本发明的技术方案。
隐丹参酮衍生物（式Ⅰ化合物）的制备与分离：
将隐丹参酮溶于二氯甲烷中，加入2倍当量的草酰氯，于室温下搅拌反应24小时，得所示化合物。将所得的反应液于旋转蒸发仪中旋干，后使用正向硅胶柱色谱分离，以300~400目硅胶为固定相；5%的二氯甲烷-石油醚混合溶剂为流动相，即可获得式Ⅰ化合物
(式Ⅰ)(R)-1-chloro-2-(1-methoxypropan-2-yl)-8,8-dimethyl-5,6,7,8-tetrahydrophenanthrene-3,4-dione。长时间的搅拌反应过程中，草酰氯会逐渐吸收空气中的水，进而使反应得以正常进行，最终得到(R)-1-chloro-2-(1-methoxypropan-2-yl)-8,8-dimethyl-5,6,7,8-tetrahydrophenanthrene-3,4-dione。
隐丹参酮衍生物（式Ⅰ化合物）结构确证数据：
1H NMR
(CDCl3, 400MHz)
δ 7.96 (1H, d,
J
= 8.3 Hz, H-9), 7.88 (1H, d,
J = 8.3 Hz, H-10), 4.53 (1H, dd,
J = 10.6 and 6.4 Hz, H-16a), 4.44 (1H, dd,
J = 10.6 and 6.4 Hz, H-16b), 3.75 (1H, dq,
J = 14.2 and 7.0 Hz, H-15), 3.23 (2H, t,
J
= 6.34 Hz, H-1), 1.98 (3H, s, H-17), 1.85 (2H, m, H-2), 1.73 (2H, m, H-3), 1.39
(3H, d,
J = 7.3 Hz, H-18), 1.37 (6H, s, H-19,20).
13C NMR
(CDCl3, 400MHz)
δ184.0 (C, C-11),
180.3 (C, C-12), 172.6 (C, C-14), 155.3 (C, C-13), 146.6 (C, C-5), 141.7 (C,
C-6), 134.0 (CH, C-10), 132.8 (C, C-8), 130.0 (C, C-7), 125.9 (CH, C-9), 67.7
(CH
2, C-16), 39.0 (CH
2, C-1), 37.3 (CH, C-15), 36.1(C,
C-4), 32.1 (CH
3× 2, C-18,19),
31.1 (CH
2, C-3), 20.7 (CH
3, C-17), 20.3(CH
2,
C-2), 15.3(CH
3, C-18)。
HRMS (ESI)
m/
z:
[M + H]
+ Calcd for C
20H
23ClO
3
3147.1359; Found 347.1348。
式Ⅰ化合物对脂肪细胞内甘油三酯含量的影响
化合物降脂测试应用小鼠前脂肪细胞3T3-L1细胞分化模型，采用油红O染色并结合甘油三酯定量检测，评价本发明提供的抗肥胖症化合物对脂肪细胞内甘油三酯含量影响。对数生长期的3T3-L1前脂肪细胞，5.0*10
4细胞/孔，均匀接种至48孔板，细胞培养箱静置培养，每两天更换一次培养液。待细胞生长接近至80％融合，更换培养液，继续培养2天至细胞完全融合(Day 0),更换含有分化诱导液Ⅰ的DMEM完全培养液(含10％FBS及1％双抗的DMEM培养液)，37℃5％CO
2静置培养3天(Day 3)。3天后，更换含有分化诱导液Ⅱ的DMEM完全培养液继续培养3天(Day 6)。对于药物干预组，以含分化诱导液的DMEM完全培养液为稀释液，稀释式Ⅰ化合物溶液至一定浓度，在Day 0与Day 3时，一同加入。空白对照组与分化对照组，分别加入等体积的DMSO溶液。在Day 6时，进行油红O染色拍照以及甘油三酯含量分析。
(1)分化诱导液配制
分化诱导液Ⅰ：含500μM 3-异丁基-1-甲基-黄嘌呤，100ng/mL地塞米松，2μg/mL胰岛素的DMEM完全培养液。
分化诱导液Ⅱ：含2μM含诱导液胰岛素的DMEM完全培养液。
(2)油红O染色
细胞诱导分化至Day 6时，细胞经预冷PBS润洗1次，4％冰冻多聚甲醛固定液室温固定60min。0.3％油红O染色工作液室温染色30min。室温的去离子水漂洗2-3次，倒置显微镜拍照(40倍)。每孔分别加入300uL异丙醇溶液，摇床平缓摇动室温萃取油红O染料30min，分别移取100μM染液进行510nm吸光度检测。
(3)甘油三酯含量分析
细胞分化结束后，预冷PBS润洗2次，去尽PBS，加入含0.2％Triton X-100的去离子溶液，室温静置1h，收集细胞悬液，超声破碎10min，使细胞充分裂解，离心收集上清液，按照甘油三酯检测试剂盒说明书测定甘油三酯含量。
(4)实验结果
实验结果(图3～6)显示，随着加入式Ⅰ化合物剂量的提升，细胞中被油红O染为红色的区域明显减少，说明式Ⅰ化合物能有效的抑制脂肪生成，且呈一定的剂量依赖关系。
以上是对本发明所作的进一步详细说明，不可视为对本发明的具体实施的局限。对于本发明所属技术领域的普通技术人员来说，在不脱离本发明构思的简单推演或替换，都在本发明的保护范围之内。
Claims (11)
- 一种隐丹参酮衍生物及其可接受的药用盐，所述隐丹参酮衍生物的结构式如式Ⅰ所示：式Ⅰ。
- 权利要求1所述的隐丹参酮衍生物的制备方法，包括如下步骤：将隐丹参酮溶于有机溶剂中，加入草酰氯，搅拌反应充分，反应环境的相对湿度不低于80%；将反应物分离纯化，得到式Ⅰ所示化合物。
- 根据权利要求2所述的制备方法，其特征在于：所述有机溶剂为二氧甲烷。
- 根据权利要求2所述的制备方法，其特征在于：草酰氯相对隐丹参酮过量加入。
- 根据权利要求2所述的制备方法，其特征在于：反应温度为20～30℃。
- 根据权利要求2所述的制备方法，其特征在于：所述分离纯化方法为正向硅胶柱色谱分离，以300～400目硅胶为固定相；5%的二氯甲烷-石油醚混合溶剂为流动相，即可分离纯化获得式Ⅰ化合物。
- 一种降脂或抗肥胖的组合物，其特征在于：所述组合物中的活性成分包括权利要求1所述的隐丹参酮衍生物及其可接受的药用盐中的至少一种。
- 根据权利要求7所述的组合物，其特征在于：所述组合物为口服制剂。
- 化合物在制备降脂或抗肥胖组合物的中的应用，其特征在于：所述化合物为权利要求1所述的隐丹参酮衍生物及其可接受的药用盐。
- 一种降脂或减肥的方法，包括给予脂质水平大于或体重大于正常水平的人群给予有效量的。
- 根据权利要求10所述的方法，其特征在于，体重大于正常水平指身体质量指数(BMI)≥24。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110654353.3 | 2021-06-10 | ||
| CN202110654353.3A CN113402372A (zh) | 2021-06-10 | 2021-06-10 | 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022257995A1 true WO2022257995A1 (zh) | 2022-12-15 |
Family
ID=77683654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/097739 WO2022257995A1 (zh) | 2021-06-10 | 2022-06-08 | 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113402372A (zh) |
| WO (1) | WO2022257995A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113402372A (zh) * | 2021-06-10 | 2021-09-17 | 广州中大南沙科技创新产业园有限公司 | 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 |
| CN113307731A (zh) * | 2021-06-10 | 2021-08-27 | 广州中大南沙科技创新产业园有限公司 | 一种隐丹参酮衍生物及其制备方法与在抗心肌纤维化中的应用 |
| CN117487154A (zh) * | 2023-10-31 | 2024-02-02 | 暨南大学 | 一种丹参酮衍生物及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603861A (zh) * | 2012-02-25 | 2012-07-25 | 中国科学院昆明植物研究所 | 丹参酮衍生物及其药物组合物和其在医药中的用途 |
| CN106798737A (zh) * | 2017-01-09 | 2017-06-06 | 中山大学 | 用于防治肺纤维化的隐丹参酮类及其应用 |
| CN113402372A (zh) * | 2021-06-10 | 2021-09-17 | 广州中大南沙科技创新产业园有限公司 | 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100818586B1 (ko) * | 2003-12-30 | 2008-04-01 | 주식회사 케이티앤지 | 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제 |
| CN1901900A (zh) * | 2003-12-30 | 2007-01-24 | Md白奥阿尔法有限公司 | 用增强代谢活性的丹参衍生物治疗肥胖和代谢综合症 |
| CN101590063A (zh) * | 2008-05-26 | 2009-12-02 | 中国科学院上海生命科学研究院 | 丹参酮iia在制备治疗肥胖及胰岛素抵抗的药物中的应用 |
| CN102127037A (zh) * | 2011-01-11 | 2011-07-20 | 上海交通大学 | 丹参酮类化合物及其应用 |
-
2021
- 2021-06-10 CN CN202110654353.3A patent/CN113402372A/zh active Pending
-
2022
- 2022-06-08 WO PCT/CN2022/097739 patent/WO2022257995A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603861A (zh) * | 2012-02-25 | 2012-07-25 | 中国科学院昆明植物研究所 | 丹参酮衍生物及其药物组合物和其在医药中的用途 |
| CN106798737A (zh) * | 2017-01-09 | 2017-06-06 | 中山大学 | 用于防治肺纤维化的隐丹参酮类及其应用 |
| CN113402372A (zh) * | 2021-06-10 | 2021-09-17 | 广州中大南沙科技创新产业园有限公司 | 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 |
Non-Patent Citations (1)
| Title |
|---|
| PING XIAOFAN , YONG GUO , HUA ZHU , YING XUE , DAIQIAN XIE: "Theoretical Study on the Structure Transformations of Cryptotanshinone and Tanshinone I with Hydrion or Hydroxide Ion", JOURNAL OF THEORETICAL AND COMPUTATIONAL CHEMISTRY, vol. 8, no. 2, 31 December 2009 (2009-12-31), US , pages 204 - 213, XP009541822, ISSN: 0219-6336, DOI: 10.1142/S0219633609004757 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113402372A (zh) | 2021-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022257995A1 (zh) | 一种隐丹参酮衍生物及其制备方法和降脂抗肥胖的应用 | |
| Nie et al. | Assessment of in vitro cardiotoxicity of extract fractions and diterpene alkaloids from Aconitum leucostomum Worosch: a short communication | |
| CN115010720B (zh) | 中甸艾中倍半萜二聚体及其药物组合物与其制备方法和应用 | |
| CN110590873B (zh) | 一种合欢皮新木脂体化合物 | |
| WO2004039759A1 (fr) | Compose naturel servant dans le traitement de diabetes, sa preparation et son utilisation | |
| CN105152894B (zh) | 甘松马兜铃烷型倍半萜类化合物以及制备方法与应用 | |
| CN114262294B (zh) | 一种苯基异喹啉生物碱化合物及其制备方法与应用 | |
| US20230022783A1 (en) | Preparation and application of triterpenoids with effect of improving glucose and lipid metabolism disorders | |
| Pollo et al. | A new polyacetylene glucoside from Vernonia scorpioides and its potential antihyperglycemic effect | |
| CN108059592B (zh) | 去氧甘松香醇a及其制备方法与应用 | |
| CN105837595A (zh) | 阿替洛尔的药物组合物及其在生物医药中的应用 | |
| CN113717105B (zh) | 一种二萜生物碱型化合物及其提取方法和应用 | |
| WO2022257994A1 (zh) | 一种隐丹参酮衍生物及其制备方法与在抗心肌纤维化中的应用 | |
| CN105384717B (zh) | 甘松新酮类化合物及其制备方法与应用 | |
| CN111647036B (zh) | 一类Ocotillol型酯化衍生物及其制备方法和制作抗炎药物的用途 | |
| CN114989234A (zh) | 一种山茱萸中环烯醚萜苷化合物c的制备方法及其应用 | |
| CN108948040B (zh) | 一种烟管头草中提取的吉玛烷型倍半萜化合物及其应用 | |
| CN108785316A (zh) | 香加皮c21甾类在制备ido抑制剂中的用途 | |
| CN103393637B (zh) | 黄酮类化合物在制备抗代谢性疾病药物中的用途 | |
| CN110559307A (zh) | 一种合欢皮新木脂体化合物及其新用途 | |
| CN110240583A (zh) | 一种苯并吡喃类化合物、及其制备方法和药物组合物与用途 | |
| CN113264975B (zh) | 一种刺梨根茎中提取的具有抗炎活性的提取物及其应用 | |
| CN104224796B (zh) | 齐墩果烷型三萜类酯衍生物抗神经退行性药物用途 | |
| CN112300185B (zh) | 肝毒性降低的生物碱类化合物及其制备方法和用途 | |
| CN110204477B (zh) | 一种具有抗氧化作用的二萜生物碱及其在制备药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22819592 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22819592 Country of ref document: EP Kind code of ref document: A1 |